Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-98293235ce75cd341e491c62f161e333"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-98293235ce75cd341e491c62f161e333"/>
<resource>
<Composition>
<id value="composition-en-98293235ce75cd341e491c62f161e333"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-98293235ce75cd341e491c62f161e333"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-98293235ce75cd341e491c62f161e333</b></p><a name="composition-en-98293235ce75cd341e491c62f161e333"> </a><a name="hccomposition-en-98293235ce75cd341e491c62f161e333"> </a><a name="composition-en-98293235ce75cd341e491c62f161e333-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/440/001-007</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - tyverb</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/440/001-007"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mp98293235ce75cd341e491c62f161e333"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - tyverb"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What Tyverb is and what it is used for</li><li>What you need to know before you take Tyverb</li><li>How to take Tyverb</li><li>Possible side effects</li><li>How to store Tyverb</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What tyverb is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What tyverb is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Tyverb is used to treat certain types of breast cancer (HER2-overexpressing) which have spread beyond the original tumour or to other organs (advanced or metastatic breast cancer). It may slow or stop cancer cells from growing, or may kill them.</p><p>Tyverb is prescribed to be taken in combination with another anti-cancer medicine.</p><p>Tyverb is prescribed in combination with capecitabine, for patients who have had treatment for advanced or metastatic breast cancer before. This previous treatment for metastatic breast cancer must have included trastuzumab.</p><p>Tyverb is prescribed in combination with trastuzumab, for patients who have hormone receptor- negative metastatic breast cancer and have had other treatment for advanced or metastatic breast cancer before.</p><p>Tyverb is prescribed in combination with an aromatase inhibitor, for patients with hormone sensitive metastatic breast cancer (breast cancer that is more likely to grow in the presence of hormones), who are not currently intended for chemotherapy.</p><p>Information about these medicines is described in separate patient information leaflets. Ask your doctor to give you information about these other medicines.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take tyverb"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take tyverb"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take Tyverb</p><ul><li>if you are allergic to lapatinib or any of the other ingredients of this medicine (listed in Section 6).</li></ul><p>Take special care with Tyverb</p><p>Your doctor will run tests to check that your heart is working properly before and during your treatment with Tyverb.</p><p>Tell your doctor if you have any heart problems before you take Tyverb.</p><p>Your doctor also needs to know before you take Tyverb:</p><ul><li>if you have lung disease</li><li>if you have inflammation of the lung</li><li>if you have any liver problems</li><li>if you have any kidney problems</li><li>if you have diarrhoea (see section 4).</li></ul><p>Your doctor will run tests to check that your liver is working properly before and during your treatment with Tyverb.</p><p>Tell your doctor if any of these apply to you.</p><p>Serious skin reactions Serious skin reactions have been seen with Tyverb. Symptoms may include skin rash, blisters and skin peeling.</p><p>Tell your doctor as soon as possible if you get any of these symptoms.</p><p>Other medicines and Tyverb Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and other medicines you bought without a prescription.</p><p>It is especially important to tell your doctor if you are taking, or have recently taken any of the following medicines. Some medicines may affect the way Tyverb works or Tyverb may affect how other medicines work. These medicines include some medicines in the following groups:</p><ul><li>St John s Wort a herb extract used to treat depression</li><li>erythromycin, ketoconazole, itraconazole, posaconazole, voriconazole, rifabutin, rifampicin, telithromycin medicines used to treat infections</li><li>cyclosporine a medicine used to suppress the immune system for example after organ transplantations</li><li>ritonavir, saquinavir medicines used to treat HIV</li><li>phenytoin, carbamazepine medicines used to treat seizures</li><li>cisapride a medicine used to treat certain digestive system problems</li><li>pimozide a medicine used to treat certain mental health problems</li><li>quinidine, digoxin medicines used to treat certain heart problems</li><li>repaglinide a medicine used to treat diabetes</li><li>verapamil a medicine used to treat high blood pressure or heart problems (angina)</li><li>nefazodone a medicine used to treat depression</li><li>topotecan, paclitaxel, irinotecan, docetaxel medicines used to treat certain types of cancer</li><li>rosuvastatin a medicine used to treat high cholesterol</li><li>medicines that decrease stomach acidity - used to treat stomach ulcers or indigestion</li></ul><p>Tell your doctor if you are taking, or have recently taken, any of these.</p><p>Your doctor will review the medicines you are currently taking to make sure you are not taking something that can t be taken with the Tyverb. Your doctor will advise you whether an alternative is available.</p><p>Tyverb with food and drink</p><p>Don t drink grapefruit juice while you are being treated with Tyverb. It can affect the way the medicine works.</p><p>Pregnancy and breast-feeding</p><p>The effect of Tyverb during pregnancy is not known. You should not use Tyverb if you are pregnant unless your doctor specifically recommends it.</p><ul><li>If you are pregnant or planning to become pregnant, tell your doctor.</li><li>Use a reliable method of contraception to avoid becoming pregnant while you re taking Tyverb and for at least 5 days after the last dose.</li><li>If you become pregnant during treatment with Tyverb, tell your doctor.</li></ul><p>It is not known whether Tyverb passes into breast-milk. Do not breast-feed while taking Tyverb and for at least 5 days after the last dose.</p><ul><li>If you are breast-feeding or planning to breast-feed, tell your doctor.</li></ul><p>Ask your doctor or pharmacist for advice before taking Tyverb if you are unsure.</p><p>Driving and using machines</p><p>You are responsible to decide if you are able to drive a motor vehicle or perform other tasks that require increased concentration. Because of the possible side effects of Tyverb, your ability to drive or operate machines could be affected. These effects are described in section 4, Possible side effects .</p><p>Tyverb contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take tyverb"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take tyverb"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you re not sure.</p><p>Your doctor will decide on the correct dose of Tyverb depending on the type of breast cancer being treated.</p><p>If you are prescribed Tyverb in combination with capecitabine, the usual dose is 5 Tyverb tablets a day, as a single dose.</p><p>If you are prescribed Tyverb in combination with trastuzumab, the usual dose is 4 Tyverb tablets a day, as a single dose.</p><p>If you are prescribed Tyverb in combination with an aromatase inhibitor, the usual dose is 6 Tyverb tablets a day, as a single dose.</p><p>Take the prescribed dose every day for as long as your doctor tells you to.</p><p>Your doctor will advise you about the dose of your other anti-cancer medicine, and how to take it.</p><p>Taking your tablets</p><ul><li>Swallow the tablets whole with water, one after the other, at the same time each day.</li><li>Take Tyverb either at least one hour before or at least one hour after food. Take Tyverb at the same time in relation to food each day for example, you could always take your tablet one hour before breakfast.</li></ul><p>While you are taking Tyverb</p><ul><li>Depending on the side effects you experience, your doctor may recommend lowering your dose or temporarily stopping your treatment.</li><li>Your doctor will also carry out tests to check your heart and liver function before and during treatment with Tyverb.</li></ul><p>If you take too much Tyverb</p><p>Contact a doctor or pharmacist immediately. If possible, show them the pack.</p><p>If you forget to take Tyverb</p><p>Don t take a double dose to make up for a forgotten dose. Just take the next dose at the scheduled time.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>A severe allergic reaction is a rare side effect (may affect up to 1 in 1,000 people) and may develop rapidly. Symptoms may include:</p><ul><li>skin rash (including itchy, bumpy rash)</li><li>unusual wheezing, or difficulty in breathing</li><li>swollen eyelids, lips or tongue</li><li>pains in muscles or joints</li><li>collapse or blackout.</li></ul><p>Tell your doctor immediately if you get any of these symptoms. Don t take any more tablets.</p><p>Very common side effects (may affect more than 1 in 10 people):</p><ul><li><p>diarrhoea (which may make you dehydrated and lead to more severe complications) Tell your doctor immediately at the first sign of diarrhoea (loose stool), as it is important that this is treated right away. Also tell your doctor immediately if your diarrhoea worsens. There is more advice on reducing the risk of diarrhoea at the end of section 4. * rash, dry skin, itching Tell your doctor if you get a skin rash. There is more advice on reducing the risk of skin rash at the end of section 4. Other very common side effects</p></li><li><p>loss of appetite</p></li><li><p>feeling sick (nausea)</p></li><li><p>being sick (vomiting)</p></li><li><p>tiredness, feeling weak</p></li><li><p>indigestion</p></li><li><p>constipation</p></li><li><p>sore mouth/mouth ulcers</p></li><li><p>stomach pain</p></li><li><p>trouble sleeping</p></li><li><p>back pain</p></li><li><p>pain in hands and feet</p></li><li><p>joint or back pain</p></li><li><p>a skin reaction on the palms of the hands or soles of the feet (including tingling, numbness, pain, swelling or reddening)</p></li><li><p>cough, shortness of breath</p></li><li><p>headache</p></li><li><p>nose bleed</p></li><li><p>hot flush</p></li><li><p>unusual hair loss or thinning</p></li></ul><p>Tell your doctor if any of these side effects get severe or troublesome.</p><p>Common side effects (may affect up to 1 in 10 people):</p><ul><li>an effect on how your heart works</li></ul><p>In most cases, the effect on your heart will not have any symptoms. If you do experience symptoms associated with this side effect, these are likely to include an irregular heartbeat and shortness of breath.</p><ul><li>liver problems, which may cause itching, yellow eyes or skin (jaundice), or dark urine or pain or discomfort in the right upper area of the stomach</li><li>nail disorders such as a tender infection and swelling of the cuticles</li><li>skin fissures (deep cracks on the skin or chapped skin)</li></ul><p>Tell your doctor if you get any of these symptoms.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><ul><li>treatment-induced lung inflammation, which may cause shortness of breath or cough Tell your doctor immediately if you get either of these symptoms.</li></ul><p>Other uncommon side effects include:</p><ul><li>blood tests results that show changes in liver function (usually mild and temporary)</li></ul><p>Rare side effects (may affect up to 1 in 1,000 people):</p><ul><li>severe allergic reactions (see the beginning of section 4)</li></ul><p>The frequency of some side effects is not known (it cannot be estimated from the available data):</p><ul><li>irregular heart-beat (change in the electrical activity of the heart)</li><li>severe skin reaction that might include: rash, red skin, blistering of the lips, eyes or mouth, skin peeling, fever or any combination of these</li><li>pulmonary arterial hypertension (increased blood pressure in the arteries (blood vessels) of the lungs)</li></ul><p>If you get other side effects</p><p>Tell your doctor or pharmacist if you notice any side effects not listed in this leaflet.</p><p>Reducing the risk of diarrhoea and skin rash</p><p>Tyverb can cause severe diarrhoea</p><p>If you suffer from diarrhoea while taking Tyverb:</p><ul><li>drink plenty of fluids (8 to 10 glasses a day), such as water, sports drinks or other clear liquids</li><li>eat low-fat, high protein foods instead of fatty or spicy foods</li><li>eat cooked vegetables instead of raw vegetables and remove the skin from fruits before eating</li><li>avoid milk and milk products (including ice cream)</li><li>avoid herbal supplements (some may cause diarrhoea).</li></ul><p>Tell your doctor if your diarrhoea continues.</p><p>Tyverb can cause skin rash</p><p>Your doctor will check your skin before and during treatment. To care for sensitive skin:</p><ul><li>wash with a soap-free cleanser</li><li>use fragrance free, hypoallergenic beauty products</li><li>use sunscreen (Sun Protection Factor [SPF] 30 or higher).</li></ul><p>Tell your doctor if you get a skin rash.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store tyverb"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store tyverb"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the blister or bottle and the carton.</p><p>Do not store above 30 C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What Tyverb contains</p><ul><li>The active substance in Tyverb is lapatinib. Each film-coated tablet contains lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib.</li><li>The other ingredients are: microcrystalline cellulose, povidone (K30), sodium starch glycolate (Type A), magnesium stearate, hypromellose, titanium dioxide (E171), macrogol (400), polysorbate 80, iron oxide yellow (E172), and iron oxide red (E172).</li></ul><p>What Tyverb looks like and contents of the pack</p><p>Tyverb film-coated tablets are oval, biconvex, yellow film-coated, with GS XJG marked on one side.</p><p>Tyverb is supplied in either blisters packs or bottles:</p><p>Blister packs Each pack of Tyverb contains 70 or 84 tablets in aluminium foil blisters of 10 or 12 tablets each. Each foil has a perforation down the middle and can be divided into two blisters with 5 or 6 tablets in each, depending on the pack size.</p><p>Tyverb is also available in multipacks containing 140 tablets that comprise 2 packs, each containing 70 tablets.</p><p>Bottles Tyverb is also available in plastic bottles containing 70, 84, 105 or 140 tablets.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Novartis Europharm Limited Vista Building Elm Park, Merrion Road Dublin 4 Ireland</p><p>Manufacturer Glaxo Wellcome S.A. Avenida de Extremadura 3 09400 Aranda de Duero Burgos Spain</p><p>Novartis Pharma GmbH Roonstra e D-90429 Nuremberg Germany</p><p>Novartis Farmac utica S.A. Gran Via de les Corts Catalanes, 08013 Barcelona Spain</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Novartis Pharma N.V. T l/Tel: +32 2 246 16 Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16<br/>Novartis Bulgaria EOOD : +359 2 489 98 Luxembourg/Luxemburg Novartis Pharma N.V. T l/Tel: +32 2 246 16 esk republika Novartis s.r.o. Tel: +420 225 775 Magyarorsz g Novartis Hung ria Kft. Tel.: +36 1 457 65 Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 Malta Novartis Pharma Services Inc. Tel: +356 2122 2Deutschland Novartis Pharma GmbH Tel: +49 911 273 0</p><p>Nederland Novartis Pharma B.V. Tel: +31 88 04 52 Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 Norge Novartis Norge AS Tlf: +47 23 05 20<br/>Novartis (Hellas) A.E.B.E. : +30 210 281 17 sterreich Novartis Pharma GmbH Tel: +43 1 86 6Espa a Novartis Farmac utica, S.A. Tel: +34 93 306 42 Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4France Novartis Pharma S.A.S. T l: +33 1 55 47 66 Portugal Novartis Farma - Produtos Farmac uticos, S.A. Tel: +351 21 000 8Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 Rom nia Novartis Pharma Services Romania SRL Tel: +40 21 31299 Ireland Novartis Ireland Limited Tel: +353 1 260 12 Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 sland Vistor hf. S mi: +354 535 7Slovensk republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133<br/>Novartis Pharma Services Inc. : +357 22 690 Sverige Novartis Sverige AB Tel: +46 8 732 32 Latvija SIA Novartis Baltics Tel: +371 67 887 United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mp98293235ce75cd341e491c62f161e333"/>
<resource>
<MedicinalProductDefinition>
<id value="mp98293235ce75cd341e491c62f161e333"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mp98293235ce75cd341e491c62f161e333"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mp98293235ce75cd341e491c62f161e333</b></p><a name="mp98293235ce75cd341e491c62f161e333"> </a><a name="hcmp98293235ce75cd341e491c62f161e333"> </a><a name="mp98293235ce75cd341e491c62f161e333-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/07/440/001-007</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Tyverb 250 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/07/440/001-007"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="Tyverb 250 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
